Sinotherapeutics Salute del bilancio

Salute finanziaria criteri di controllo 0/6

Informazioni chiave

0.002%

Rapporto debito/patrimonio netto

CN¥22.09k

Debito

Indice di copertura degli interessi	-9x
Contanti	CN¥747.64m
Patrimonio netto	CN¥1.24b
Totale passività	CN¥192.42m
Totale attività	CN¥1.43b

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Concerns Surrounding Sinotherapeutics' (SHSE:688247) Performance

Nov 02

Sinotherapeutics Salute del bilancio

Salute finanziaria criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Investor sentiment improves as stock rises 16%

Concerns Surrounding Sinotherapeutics' (SHSE:688247) Performance

New major risk - Earnings quality

New minor risk - Dividend sustainability

Sinotherapeutics Inc. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 27%

Second quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.029 in 2Q 2023)

Sinotherapeutics Inc. to Report First Half, 2024 Results on Aug 31, 2024

Sinotherapeutics Inc., Annual General Meeting, May 31, 2024

First quarter 2024 earnings released: EPS: CN¥0.05 (vs CN¥0.02 in 1Q 2023)

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 18%

Sinotherapeutics Inc. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.22 in FY 2022)

Sinotherapeutics Inc. (SHSE:688247) announces an Equity Buyback for CNY 70 million worth of its shares.

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 19%

Third quarter 2023 earnings released: EPS: CN¥0.052 (vs CN¥0.059 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.029 (vs CN¥0.05 in 2Q 2022)

Investor sentiment improves as stock rises 16%

Sinotherapeutics Inc. to Report First Half, 2023 Results on Aug 30, 2023

Investor sentiment deteriorates as stock falls 19%

Full year 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.33 in FY 2021)

Investor sentiment improves as stock rises 17%

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.059 (vs CN¥0.12 in 3Q 2021)

Investor sentiment improved over the past week

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane